Blue light-filtering IOL significantly reduces driving glare disability

Article

Using blue light-filtering IOLs, as opposed to UV-only filtering non-toric IOLs, produces a significantly greater reduction in glare disability when driving.

Using blue light-filtering IOLs, as opposed to UV-only filtering non-toric IOLs, produces a significantly greater reduction in glare disability when driving, reveals an investigation in the Journal of Cataract and Refractive Surgery.

Dr Rob Gray and his team, Department of Applied Psychology, Arizona State University, Mesa, Arizona, USA, conducted a comparative case series on patients wearing a blue light-filtering IOL (the test IOL) or an ultraviolet (UV)-only filtering non-toric IOL (the control IOL).

Patients were asked to perform left-turn manoeuvres in a driving simulator while wearing best spherocylindrical correction. Time to collision minus the time taken to turn at a junction into oncoming traffic was used to define the safety margin. The same process was repeated but during daytime driving conditions with a glare source.

The test IOL was administered to 18 patients and the control IOL was given to 15 patients. Safety margins were significantly greater in patients with the test IOL in situations where glare was present.

Patients with the test IOL presented with a significantly lower glare susceptibility than the control patients. The blue light-filtering IOL enabled drivers to turn left in situations where glare is present.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.